Skip to content

Lasunadi Vati and Pippaladyasava in the management of Loss of appetite.

Clinical evaluation of Lasunadi Vati and Pippaladyasava in the management of Agnimandya.

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/01/049085
Enrollment
330
Registered
2023-01-18
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K929- Disease of digestive system, unspecified

Interventions

None listed

Sponsors

Central Council for Research in Ayurvedic Sciences. New-Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either sex with age between 18 and 60 years. 2. Patients having any six sign and symptoms of Agnimandya out of 10 along with reduced Abhyavaharan Shakti, (capacity to eat), Jarana Shakti (capacity to digest), and Ruchi (appetite) for the past one week. Avipaka, Aruchi, Udaragaurava, Shirogaurava, Praseka, Chhardi, Kasa, Shwasa, Gatrasada, Malavarodha. 3.Willing to participate in the study.

Exclusion criteria

Exclusion criteria: 1. Patients of age 60 years. 2. Patients in whom Agnimandya is caused due to intake of medicine. 3. Patients having Tikshagni (hyper functioning of digestion and metabolic activities) and Samagni (moderate Agni) 4. Patients having any established disease of Gastro-intestinal tracts. 5. Immuno compromised states and patients with systemic infections or known cases of AIDS, HIV, STD etc. 6. Patients with severe/history of cardiac, hepatic, cerebrovascular disease, pulmonary dysfunction, malignancy, chronic uncontrolled systemic diseases or renal disorder (S. Creatinine >1.2 mg/dl) etc or poorly controlled Hypertension (Blood pressure more than 160/100mm of Hg), uncontrolled Diabetes Mellitus (HbA1c � 8), or any other serious medical illness. 7. Patients on medication with corticosteroids or any other drugs that may have an influence on the outcome of the study. 8. History of hypersensitivity to the trial drug or any of its ingredients. 9. Patients who have completed participation in any other clinical trial during the past three months. 10. Any other condition, which the Investigator thinks, may jeopardize the study.

Design outcomes

Primary

MeasureTime frame
Change in sign and symptoms of Agnimandya.Timepoint: Day 0, Day 7, Day 14 and Day 21

Secondary

MeasureTime frame
Change in Agnibala (Agni Pariksha tool developed by CCRAS).Timepoint: Day 0, Day 14 and Day 21;Change in quality of life by using SF-36 ScoreTimepoint: Day 0, & Day 21

Countries

India

Contacts

Public ContactDr Dara Singh Rotwar

M.S. Regional Ayurveda Research Institute

dsrotwar7@gmail.com8827753466

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 27, 2026